Plasma ceramides and correlation with adiponectin levels in children and adolescents with type 2 diabetes.

Study ID
STU 022011-139

Cancer Related
No

Healthy Volunteers
Yes

Study Sites

Contact
Jordan Streetman
214-456-2106
jordan.streetman@childrens.com

Principal Investigator
Ximena Lopez

Summary

This is a cross-sectional study that will consist of a single visit. 30 obese subjects ages 10-17 with type 2 diabetes and 30 obese subjects with normal glycemia will be compared to a control group consisting of 30 lean subjects without diabetes of the same age group.

Subjects who meet the inclusion criteria based on information available from their medical records will be invited to participate. When patients come for their standard medical care visit or to participate in a class in the endocrinology Center, after written informed consent is obtained, 5 cc of blood will be collected for the study (at the time blood is drawn for standard medical care tests, if they are being performed).

General information from each patient will be obtained from the medical record, including: medical record number, date of birth, date of visit, gender, ethnicity, race, body mass index, weight, height, blood pressure, abdominal circumference, temperature (temporal), Tanner staging within 6 months before or after date of study screening visit, list of diagnoses and past medical history, list and dose of current medications. also the results of laboratory tests (if available) will be obtained, including: fasting glucose and insulin, Hba1c, low density cholesterol, high density cholesterol, triglycerides, aST, aLT, TSH, free T4, vitamin D25.

The blood obtained will be analyzed in Professor Philipp Scherer's Laboratory (Touchstone Diabetes Center, uTSW south campus). Plasma concentrations of total ceramides, ceramide subspecies (C18:0, C20:0, C24:1, C20:0), S1P and adiponectin will be measured in all samples. unused specimen at this time will be stored.

Total plasma ceramide, ceramide subspecies (C18:1, C18:0, C20:0, C24:1, C24:0), and S1P concentrations in subjects with type 2 diabetes or obesity without type 2 diabetes, will be compared to those of the control group. adiponectin concentrations will be correlated with total plasma ceramides and its subspecies (C18:1, C18:0, C20:0, C24:1, C24:0), as well as with S1P levels.

Participant Eligibility

Type 2 diabetes group:

a) Males and Females ages 10-17
b) Type 2 diabetes diagnosed according to ADA criteria
c) BMI >= 95th percentile
d) Any type of diabetes treatment
e) HbA1c >= 6.5%
f) Informed written consent obtained before any study-related activities (study-related activities are any procedures that would not have been performed during normal management of the subject).

Obesity group:

a) Males and Females ages 10-17
b) No type 2 diabetes according to ADA criteria
c) BMI >= 95th percentile
d) Diagnosis does not interfere with the endpoint of the study (ceramide and adiponectin levels). These subjects are available through Children[Single Quote]s Medical Center Endocrinology Center.
e) Informed written consent obtained before any study-related activities (study-related activities are any procedures that would not have been performed during normal management of the subject).

Control group:
a) Males and Females age 10-17
b) No previous diagnosis of diabetes
c) BMI <85th percentile
d) Diagnosis does not interfere with the endpoint of the study (ceramide and adiponectin levels). These subjects are available through Children[Single Quote]s Medical Center Endocrinology Center and Adolescent Clinic
e) Informed written consent obtained before any study-related activities (study-related activities are any procedures that would not have been performed during normal management of the subject).